India Globalization Capital Nominates Mr. John E. Lynch to its Board of Directors
23 December 2020 - 12:00AM
Business Wire
India Globalization Capital, Inc. (NYSE American: IGC), today
announced that John E. Lynch has been nominated as a Class A
independent director for election at the Company’s 2020 Annual
Meeting of Stockholders, to be held on January 11, 2021, replacing
Class A director Sudhakar Shenoy.
Mr. Lynch is an intellectual property attorney, admitted to
practice before the Supreme Court of the United States, the United
States Court of Appeals for the Second Circuit, and the United
States Court of Appeals for the Federal Circuit, among other
courts. He is a former partner of the law firm Fulbright &
Jaworski L.L.P.
Mr. Lynch helped negotiate the licensing of the patent filed by
the University of South Florida titled “Extreme Low Dose THC as a
Therapeutic and Prophylactic Agent for Alzheimer’s Disease”, which
is the basis for our Drops of ClarityTM product HyalolexTM,
available only in Puerto Rico, as well as the IGC-AD1 formulation,
subject of a Phase 1 trial for which we are currently enrolling
patients.
Mr. Lynch has been an independent consultant since 2003, and,
for the past five years, he has served IGC as an Advisor. Mr. Lynch
has been instrumental in developing the intellectual property
strategy for the Company. Thanks to Mr. Lynch’s strategy and
support, the Company has filed eleven patents with the United
States Patent & Trademark Office (USPTO) including formulations
for Cannabidiol-based compositions and methods for treating pain,
cachexia and eating disorders, seizures, CNS disorders, restoring
energy, stuttering and Tourette syndrome (TS), and Alzheimer’s
disease related symptoms.
Mr. Lynch was an adjunct professor of law at Georgetown
University Law Center, as well as an adjunct professor in
Intellectual Property (IP) Law at the University of San Francisco
School of Law. Mr. Lynch received a B.S., Chemistry, in 1960 from
Fordham College and a J.D. in 1963 from Georgetown University Law
Center.
We thank Mr. Shenoy for his guidance over the past fourteen
years, and, while he will no longer be a director on the board, we
will continue to seek his valuable advice.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201222005158/en/
Claudia Grimaldi 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Apr 2024 to May 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From May 2023 to May 2024